Randomized trial · people

Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes and severe obesity, efinopegdutide lowered weight in a dose-linked way over 12 weeks, but it did not improve blood sugar control and caused more nausea and vomiting than placebo.

Kind
Randomized trial
Studied in
People
Number studied
195
Published
2021
Journal
Clin Obes

What they tested

This phase 2 study compared three doses of efinopegdutide with placebo to see how much weight people with type 2 diabetes and class II/III obesity lost over 12 weeks, and how safe the drug was.

How the study was done

A phase 2, randomized, double-blind, placebo-controlled trial in 195 dosed people with type 2 diabetes (HbA1c, a long-term average of blood sugar, of 6.5%-9.5%) and a body mass index of 35 to 50 kg/m2. They were split evenly into placebo (a dummy treatment) or a 5.0 mg, 7.4 mg or 10.0 mg arm, and the main measure was percent change in body weight at week 12.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

After removing the placebo effect, body weight fell by 4.6% in the 5.0 mg arm, 5.9% in the 7.4 mg arm and 7.2% in the 10.0 mg arm at week 12, with bigger doses giving more weight loss. HbA1c did not change at any dose, fasting insulin rose slightly, and fasting blood sugar went up in the 5.0 mg and 7.4 mg arms. Side effects, mainly nausea and vomiting, were more common than on placebo, and 144 of 195 people (73.8%) finished treatment.

What it doesn’t show

This was a short 12-week dose-finding trial, so it does not show whether the weight loss lasts or what happens over longer use. About a quarter of participants did not complete treatment.

The paper

Di Prospero et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clin Obes. 2021.

The compound

More studies on Efinopegdutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo